Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
BMY has been having a good run for the past three months. The stock recently touched a 52-week high.
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.
What's Next For BMY Stock After An Upbeat Q3?
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It reported revenue of $11.9 billion and adjusted earnings of $1.80 per...
Stock Market Rally Is 2 Years Old: 3 Passive Income Favorites Are November Bargains
24/7 Wall St. Insights The long AI-driven rally has many tech stocks overvalued.
Bristol Myers Stock Rises After Earnings Beat, Guidance Hike
The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.
BMY or VRTX: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offer...
A Market Crash Could Ruin Baby Boomers: 5 Safe High-Yield Dividend Stocks and Advice
24/7 Wall St. Insights The 2025 Social Security COLA will be only 2.5%.
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $52.20, denoting a -0.38% change from the preceding trading day.
Bristol Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Frequent trading can erode gains due to transaction costs and taxes; a buy-and-hold strategy is often more effective for retail investors. Bristol Myers Squibb offers a strong dividend yield, below...
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
2 Passive-Income Stocks to Load Up On in October
These two dividend powerhouses are ideal choices for passive-income investors.
3 Surprisingly Underrated Stocks to Buy Right Now
Bristol Myers Squibb is trading at a significant discount. Moderna has a lot of irons in the fire.
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is poised to rise due to the FDA approval of Cobenfy, a novel antipsychotic for schizophrenia, and improved technicals. The company's $14 billion acquisition of Karuna ...
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna for $14bn and the subsequent FDA approval of Cobenfy, a novel schizophrenia drug, represents a significant strategic win. Cobenfy, the first new schizop...
Related Companies